Amodiaquine
Camoquin (amodiaquine) is a small molecule pharmaceutical. Amodiaquine was first approved as Camoquin hydrochloride on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amodiaquine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CAMOQUIN HYDROCHLORIDE | Pfizer | N-006441 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
144 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | 2 | 10 | 1 | — | 3 | 15 | |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 6 | 5 | 1 | — | 2 | 12 |
| Basal cell neoplasms | D018295 | 1 | 1 | 1 | — | 1 | 3 | ||
| Phototherapy | D010789 | — | — | 1 | — | — | 1 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 1 | — | — | 1 |
| Male breast neoplasms | D018567 | — | — | 1 | — | — | 1 | ||
| Meningioma | D008579 | EFO_0003098 | D32.9 | — | — | 1 | — | — | 1 |
| Transitional cell carcinoma | D002295 | — | — | 1 | — | — | 1 | ||
| Skin aging | D015595 | EFO_0005422 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acne vulgaris | D000152 | EFO_0003894 | L70 | 1 | 4 | — | — | 5 | 10 |
| Photochemotherapy | D010778 | 2 | 1 | — | — | 1 | 3 | ||
| Astrocytoma | D001254 | EFO_0000271 | 2 | 1 | — | — | — | 3 | |
| Basal cell nevus syndrome | D001478 | EFO_0004136 | — | 1 | — | — | 1 | 2 | |
| Neoplasms | D009369 | C80 | 1 | 1 | — | — | — | 2 | |
| Erythroplasia | D004919 | EFO_1001786 | D00-D09 | 1 | 2 | — | — | — | 2 |
| Leukoplakia | D007971 | HP_0002745 | 1 | 2 | — | — | — | 2 | |
| Gliosarcoma | D018316 | 1 | 1 | — | — | — | 2 | ||
| Precancerous conditions | D011230 | 1 | 1 | — | — | — | 2 | ||
| Neurofibromatosis 1 | D009456 | Q85.01 | — | 1 | — | — | — | 1 |
Show 9 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | 1 | — | — | — | 1 | 2 |
| Carcinoma in situ | D002278 | D09.9 | 1 | — | — | — | — | 1 | |
| Neurofibromatoses | D017253 | Q85.00 | 1 | — | — | — | — | 1 | |
| Mycosis fungoides | D009182 | C84.0 | 1 | — | — | — | — | 1 | |
| Seborrheic dermatitis | D012628 | L21 | 1 | — | — | — | — | 1 | |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | 1 | — | — | — | — | 1 |
| Oligodendroglioma | D009837 | EFO_0000631 | 1 | — | — | — | — | 1 | |
| Head and neck neoplasms | D006258 | 1 | — | — | — | — | 1 | ||
| Oral leukoplakia | D007972 | K13.21 | 1 | — | — | — | — | 1 | |
| Keratosis | D007642 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 2 | 2 |
| Covid-19 | D000086382 | U07.1 | — | — | — | — | 2 | 2 | |
| Sars-cov-2 | D000086402 | — | — | — | — | 2 | 2 | ||
| Sleep initiation and maintenance disorders | D007319 | F51.01 | — | — | — | — | 1 | 1 | |
| Psychological adaptation | D000223 | — | — | — | — | 1 | 1 | ||
| Squamous cell neoplasms | D018307 | — | — | — | — | 1 | 1 | ||
| Pituitary neoplasms | D010911 | — | — | — | — | 1 | 1 | ||
| Condylomata acuminata | D003218 | EFO_0007147 | A63.0 | — | — | — | — | 1 | 1 |
| Iron-deficiency anemia | D018798 | HP_0001891 | D50 | — | — | — | — | 1 | 1 |
| Hepatic porphyrias | D017094 | — | — | — | — | 1 | 1 |
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | AMODIAQUINE |
| INN | amodiaquine |
| Description | Amodiaquine is a quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position. It has a role as an antimalarial, a non-steroidal anti-inflammatory drug, a drug allergen, a prodrug, an EC 2.1.1.8 (histamine N-methyltransferase) inhibitor and an anticoronaviral agent. It is a member of phenols, an aminoquinoline, a secondary amino compound, a tertiary amino compound and an organochlorine compound. It is a conjugate base of an amodiaquine(1+). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O |
Identifiers
| PDB | — |
| CAS-ID | 86-42-0 |
| RxCUI | 720 |
| ChEMBL ID | CHEMBL682 |
| ChEBI ID | 2674 |
| PubChem CID | 2165 |
| DrugBank | DB00613 |
| UNII ID | 220236ED28 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,149 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
898 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more